LRP6 and breast carcinoma: Kallistatin inhibits breast cancer cell proliferation, migration, and invasion by binding LRP6 to block Wnt/β-catenin signaling (113), with its heparin-binding site antagonizing Wnt3a-induced proliferation (19).